CN110747489B - Preparation method of anticancer drug gefitinib and intermediates of its analogs by electroreduction - Google Patents
Preparation method of anticancer drug gefitinib and intermediates of its analogs by electroreduction Download PDFInfo
- Publication number
- CN110747489B CN110747489B CN201911078871.4A CN201911078871A CN110747489B CN 110747489 B CN110747489 B CN 110747489B CN 201911078871 A CN201911078871 A CN 201911078871A CN 110747489 B CN110747489 B CN 110747489B
- Authority
- CN
- China
- Prior art keywords
- amino
- acid derivative
- electroreduction
- methoxybenzoic acid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 239000005411 L01XE02 - Gefitinib Substances 0.000 title description 27
- 229960002584 gefitinib Drugs 0.000 title description 27
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 title description 27
- 239000000543 intermediate Substances 0.000 title description 12
- 239000002246 antineoplastic agent Substances 0.000 title description 7
- 229940041181 antineoplastic drug Drugs 0.000 title description 7
- HHNWXQCVWVVVQZ-UHFFFAOYSA-N 2-amino-4-methoxybenzoic acid Chemical class COC1=CC=C(C(O)=O)C(N)=C1 HHNWXQCVWVVVQZ-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000000243 solution Substances 0.000 claims abstract description 26
- DVZBWONCSHFMMM-UHFFFAOYSA-N 4-methoxy-2-nitrobenzoic acid Chemical class COC1=CC=C(C(O)=O)C([N+]([O-])=O)=C1 DVZBWONCSHFMMM-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 238000005868 electrolysis reaction Methods 0.000 claims abstract description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000003863 ammonium salts Chemical class 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000011259 mixed solution Substances 0.000 claims abstract description 4
- 239000003929 acidic solution Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000010949 copper Substances 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- -1 p-toluenesulfonyl Chemical group 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 239000010936 titanium Substances 0.000 claims description 4
- 229910052719 titanium Inorganic materials 0.000 claims description 4
- 235000019270 ammonium chloride Nutrition 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 claims description 3
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 2
- XZXYQEHISUMZAT-UHFFFAOYSA-N 2-[(2-hydroxy-5-methylphenyl)methyl]-4-methylphenol Chemical compound CC1=CC=C(O)C(CC=2C(=CC=C(C)C=2)O)=C1 XZXYQEHISUMZAT-UHFFFAOYSA-N 0.000 claims description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 2
- 229910001369 Brass Inorganic materials 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 2
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 claims description 2
- 239000001099 ammonium carbonate Substances 0.000 claims description 2
- 235000012501 ammonium carbonate Nutrition 0.000 claims description 2
- 229940107816 ammonium iodide Drugs 0.000 claims description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 2
- 239000010951 brass Substances 0.000 claims description 2
- 229940075397 calomel Drugs 0.000 claims description 2
- 238000005341 cation exchange Methods 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 229910002804 graphite Inorganic materials 0.000 claims description 2
- 239000010439 graphite Substances 0.000 claims description 2
- 239000011133 lead Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 description 24
- 230000008569 process Effects 0.000 description 13
- 230000009467 reduction Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 9
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000003638 chemical reducing agent Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- FYCDMKYKGPHRFW-UHFFFAOYSA-N 4-methoxy-5-(3-morpholin-4-ylpropoxy)-2-nitrobenzonitrile Chemical compound COC1=CC([N+]([O-])=O)=C(C#N)C=C1OCCCN1CCOCC1 FYCDMKYKGPHRFW-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- QPJVMBTYPHYUOC-UHFFFAOYSA-N Methyl benzoate Natural products COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940095102 methyl benzoate Drugs 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 5
- 238000006396 nitration reaction Methods 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000017858 demethylation Effects 0.000 description 3
- 238000010520 demethylation reaction Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- LUWJKZQXEIOILK-UHFFFAOYSA-N methyl 4-methoxy-5-(3-morpholin-4-ylpropoxy)-2-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC)=CC(OCCCN2CCOCC2)=C1OC LUWJKZQXEIOILK-UHFFFAOYSA-N 0.000 description 3
- GCINJZKBBZPKMT-UHFFFAOYSA-N methyl 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC(OCCCCl)=C(OC)C=C1[N+]([O-])=O GCINJZKBBZPKMT-UHFFFAOYSA-N 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- DSPAUOALMSIBJA-UHFFFAOYSA-N 2-amino-4-methoxy-5-(3-morpholin-4-ylpropoxy)benzonitrile Chemical compound COC1=CC(N)=C(C#N)C=C1OCCCN1CCOCC1 DSPAUOALMSIBJA-UHFFFAOYSA-N 0.000 description 2
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 2
- LBKFGYZQBSGRHY-UHFFFAOYSA-N 3-hydroxy-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1O LBKFGYZQBSGRHY-UHFFFAOYSA-N 0.000 description 2
- CZNVOBRARXZUEA-UHFFFAOYSA-N 4-methoxy-5-(3-morpholin-4-ylpropoxy)-2-nitrobenzamide Chemical compound COC1=CC([N+]([O-])=O)=C(C(N)=O)C=C1OCCCN1CCOCC1 CZNVOBRARXZUEA-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- DFJJAQKKQNIWOC-UHFFFAOYSA-N methyl 2-amino-4-methoxy-5-(3-morpholin-4-ylpropoxy)benzoate Chemical compound C1=C(N)C(C(=O)OC)=CC(OCCCN2CCOCC2)=C1OC DFJJAQKKQNIWOC-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- HFUBNPPCNQAACT-UHFFFAOYSA-N 2-amino-4-methoxy-5-(3-morpholin-4-ylpropoxy)benzamide Chemical compound COC1=CC(N)=C(C(N)=O)C=C1OCCCN1CCOCC1 HFUBNPPCNQAACT-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- ASQHIJLQYYFUDN-UHFFFAOYSA-N 3-hydroxy-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C=C1O ASQHIJLQYYFUDN-UHFFFAOYSA-N 0.000 description 1
- PIAZYBLGBSMNLX-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine Chemical compound ClCCCN1CCOCC1 PIAZYBLGBSMNLX-UHFFFAOYSA-N 0.000 description 1
- XSMNXXLYXKDEQC-UHFFFAOYSA-N 5-(3-chloropropoxy)-4-methoxy-2-nitrobenzonitrile Chemical compound COC1=CC([N+]([O-])=O)=C(C#N)C=C1OCCCCl XSMNXXLYXKDEQC-UHFFFAOYSA-N 0.000 description 1
- VAFJDIUJDDCMHN-UHFFFAOYSA-N 5-hydroxy-4-methoxy-2-nitrobenzoic acid Chemical compound COC1=CC([N+]([O-])=O)=C(C(O)=O)C=C1O VAFJDIUJDDCMHN-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BNVMZMDYHLRKHJ-UHFFFAOYSA-N ethyl 4-methoxy-5-(3-morpholin-4-ylpropoxy)-2-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)OCC)=CC(OCCCN2CCOCC2)=C1OC BNVMZMDYHLRKHJ-UHFFFAOYSA-N 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- XWBGJCXHTYYWHG-UHFFFAOYSA-N methyl 2-amino-5-(3-hydroxypropoxy)-4-methoxybenzoate Chemical compound COC(=O)C1=CC(OCCCO)=C(OC)C=C1N XWBGJCXHTYYWHG-UHFFFAOYSA-N 0.000 description 1
- QLOCHQYPLXTMCN-UHFFFAOYSA-N methyl 5-(3-hydroxypropoxy)-4-methoxy-2-nitrobenzoate Chemical compound COC1=C(C=C(C(=C1)[N+](=O)[O-])C(=O)OC)OCCCO QLOCHQYPLXTMCN-UHFFFAOYSA-N 0.000 description 1
- ZKUUVVYMPUDTGJ-UHFFFAOYSA-N methyl 5-hydroxy-4-methoxy-2-nitrobenzoate Chemical compound COC(=O)C1=CC(O)=C(OC)C=C1[N+]([O-])=O ZKUUVVYMPUDTGJ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
- C25B3/00—Electrolytic production of organic compounds
- C25B3/20—Processes
- C25B3/25—Reduction
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明涉及式Ⅰ所示2‑氨基‑4‑甲氧基苯甲酸衍生物的电还原制备方法，其制备反应如下：其中，n选自：1，2或3；X选自：CO2H，CO2Me，CO2Et，CO2Bn，CONH2或CN；Bn为苄基；Y选自：HO，Cl，Br，MsO，TsO或
M选自：CH或N；W选自：CH2，O，S，NH，HOCH，MeN或EtN。本发明的2‑氨基‑4‑甲氧基苯甲酸衍生物Ⅰ的电还原制备方法，其特点是，在隔膜电解槽中，以4‑甲氧基‑2‑硝基苯甲酸衍生物的酸性溶液或无机铵盐、有机溶剂和水的混合溶液作为阴极电解液；相对于参比电极，阴极工作电极电压为1.00V～2.50V；阳极电解液为酸性溶液，恒电流或恒电压电解，恒电流的电流密度在20.0mA/cm2～250.0mA/cm2之间，电解的温度在20℃～80℃之间。The present invention relates to the electroreduction preparation method of 2-amino-4-methoxybenzoic acid derivatives shown in formula I, and the preparation reaction is as follows: 
Wherein, n is selected from: 1, 2 or 3; X is selected from: CO 2 H, CO 2 Me, CO 2 Et, CO 2 Bn, CONH 2 or CN; Bn is benzyl; Y is selected from: HO, Cl, Br, MsO, TsO or M is selected from: CH or N; W is selected from: CH2 , O, S, NH, HOCH, MeN or EtN. The electroreduction preparation method of the 2-amino-4-methoxybenzoic acid derivative I of the present invention is characterized in that, in the diaphragm electrolytic cell, the acidity of the 4-methoxy-2-nitrobenzoic acid derivative is The solution or the mixed solution of inorganic ammonium salt, organic solvent and water is used as the catholyte; relative to the reference electrode, the cathode working electrode voltage is 1.00V ~ 2.50V; the anolyte is an acidic solution, constant current or constant voltage electrolysis, constant The current density of the current is between 20.0 mA/cm 2 and 250.0 mA/cm 2 , and the temperature of the electrolysis is between 20°C and 80°C.
Description
Technical Field
The invention relates to an electroreduction preparation method of an anticancer drug gefitinib and an analogue intermediate thereof, in particular to a method for preparing a 2-amino-4-methoxybenzoic acid derivative by electroreduction of a 4-methoxy-2-nitrobenzoic acid derivative (A).
Background
Gefitinib is a selective Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor, EGFR is overexpressed in certain types of human cancer cells-e.g., in solid cancers such as lung and breast cancer. Inhibition of EGFR tyrosine kinase activity can interfere with tumor growth, metastasis and angiogenesis, and increase apoptosis of tumor cells.
Dawn, zhangeiqin and the like [ a preparation method of gefitinib, CN 102030716a, 2011-04-27] describe that 3, 4-dimethoxybenzoic acid is subjected to nitration, demethylation and methyl esterification to obtain an intermediate 2-nitro-4-methoxy-5-hydroxybenzoic acid methyl ester, and then alkyl side chain is introduced for reaction to obtain gefitinib. Wherein 4-methoxy-5- (3-morpholinylpropoxy) -2-nitrobenzoic acid methyl ester is subjected to catalytic hydrogenation to prepare 2-amino-4-methoxy-5- (3-morpholinylpropoxy) benzoic acid methyl ester:
xuzhou's right et al (gefitinib synthesis research, chemical and biological engineering, 2011(1): 20-22.) describe 3-hydroxy-4-methoxybenzaldehyde, which is first converted into 3-hydroxy-4-methoxybenzonitrile, then condensed with N- (3-chloropropyl) morpholine, and then nitrated, reduced, reacted with DMF-DMA, and reacted with 3-chloro-4-fluoroaniline to synthesize gefitinib. Wherein, the reduction of 4-methoxy-5- (3-morpholinylpropoxy) -2-nitrobenzonitrile selects sodium hydrosulfite (sodium hydrosulfite) as a chemical reducing agent:
tengwei [ Gefitinib and erlotinib synthesis process research, Shenyang pharmaceutical university Master thesis, 2008] describes that 3-hydroxy-4-methoxybenzoic acid is subjected to cyanidation, etherification and nitration to generate a key intermediate 4-methoxy-5- (3-morpholinylpropoxy) -2-nitrobenzonitrile, 4-methoxy-5- (3-morpholinylpropoxy) -2-nitrobenzonitrile is reduced by sodium hydrosulfite, and then Gefitinib is obtained through two-step reaction:
chen ren macro and the like [ research on Gefitinib synthesis process, China journal of pharmacy 2012, 47(13):1084-1087] describe that veratraldehyde is subjected to nitration, selective demethylation, nucleophilic substitution, reduction, amination, ring closure and other reactions to obtain Gefitinib. Wherein, the reduction of 4-methoxy-5- (3-morpholinylpropoxy) -2-nitrobenzonitrile selects sodium hydrosulfite as a chemical reducing agent:
zheng and jimin et al [ Novel prediction of gefitinib. J Chem Research, 2009, 6: 388-; WO101148439A1, 2008-03-26 describes that sodium hydrosulfite is used as a reducing agent, and the yield is 90%. Shih et al [ Shih Kaeshyang, et al synthetic method for 6, 7-substitents-4-aniline quinazoline, WO101148439A1, 2011-12-01] describe catalytic hydrogenation at 50psi pressure with 10% Pd/C as catalyst. Although the reduction yield is high, the pressure is high, and the equipment safety requirement is high. Li-Astro et al [ A preparation method of Gefitinib, CN 102030716A, 2011-04-27] describe catalytic hydrogenation with 10% Pd/C as catalyst under normal pressure.
Sunjin and the like [ the research on a synthetic method of an anti-tumor drug gefitinib, the chemical research and the application thereof, 2013, (8) 1180-1184] takes isovanillin as a raw material, and prepares the gefitinib through reactions such as cyanation, chloropropylation, nitration, reduction, rearrangement, introduction of morpholinyl and the like. Wherein, the reduction of 4-methoxy-5- (3-chloropropoxy) -2-nitrobenzonitrile selects sodium hydrosulfite as a chemical reducing agent:
xujiankang et al (Gefitinib synthesis research. Wash. J. Pharmacology, 2012, 27(4): 362-364.) describe veratraldehyde, which was reacted in the following 10 steps to obtain Gefitinib. Wherein 4-methoxy-5- (3-hydroxy propoxy) -2-nitrobenzoic acid methyl ester is subjected to catalytic hydrogenation to prepare 2-amino-4-methoxy-5- (3-hydroxy propoxy) benzoic acid methyl ester:
the university of southeast university scholars [ Bioorg Med Chem,2010,18(11):3812-3822] describes a preparation method of 2-amino-4-methoxy-5- (3-chloropropoxy) methyl benzoate as an intermediate of an anticancer active compound, and the 4-methoxy-5- (3-chloropropoxy) -2-nitrobenzoic acid methyl ester is reduced by iron powder and acetic acid to obtain the 2-amino-4-methoxy-5- (3-chloropropoxy) methyl benzoate with the yield of 77 percent.
Chongzhang et al [4- (3-chloro-4-fluorophenylamino) -7-methoxy-6- (3-morpholinopropoxy) quinazoline preparation method CN1773738A, 2006-02-15] adopts 3, 4-dimethoxybenzoic acid as a raw material, and gefitinib is prepared through reactions such as nitration, demethylation, reduction, ring closure, chlorination, substitution, etherification and the like. Wherein the reduction of 5-hydroxy-4-methoxy-2-nitrobenzoic acid selects iron powder as a metal reducing agent:
the nitro compound adopts a catalytic hydrogenation method: the catalyst palladium is relatively expensive; the palladium catalyst and the reduction product amino compound intermediate form a complex which is difficult to separate, and the purity of the intermediate and the standard exceeding of heavy metals in anticancer drug products are influenced. The inorganic reducing agent sodium hydrosulfite, Fe/HOAc, Fe/HCl and tin dichloride have great environmental pollution; FeCl3The reduction of/C-hydrazine hydrate, hydrazine hydrate and the like seriously pollutes the environment.
Disclosure of Invention
The invention solves the technical problem of providing an electroreduction preparation method of an anticancer drug gefitinib and an analogue intermediate thereof, namely a 2-amino-4-methoxybenzoic acid derivative (I).
In order to solve the technical problem, the invention provides the following technical scheme:
the technical scheme of the invention provides an electroreduction preparation method of a 2-amino-4-methoxybenzoic acid derivative (I), which is characterized in that the 4-methoxy-2-nitrobenzoic acid derivative (A) is subjected to electroreduction to prepare the 2-amino-4-methoxybenzoic acid derivative (I), and the preparation reaction is as follows:
wherein n is selected from: 1, 2 or 3; x is selected from: CO 22H，CO2Me，CO2Et，CO2Bn，CONH2Or CN; bn is benzyl;
y is selected from: HO, Cl, Br, MsO, TsO or
Ms is methylsulfonyl; ts is p-toluenesulfonyl; w is selected from: CH (CH)2O, S, NH, HOCH, Men or EtN; m is selected from: CH or N.
Further, a process for producing a 2-amino-4-methoxybenzoic acid derivative (I) by electroreduction, wherein the 2-amino-4-methoxybenzoic acid derivative (I) is selected from the group consisting of compounds represented by the formula II:
wherein n is selected from: 1, 2 or 3; r is selected from: hydrogen, methyl, ethyl or benzyl; y is selected from: HO, Cl, Br, MsO or TsO.
Further, a process for producing a 2-amino-4-methoxybenzoic acid derivative (I) by electroreduction, wherein the 2-amino-4-methoxybenzoic acid derivative (I) is selected from the group consisting of compounds represented by the following formula III:
wherein n is selected from: 1, 2 or 3; r is selected from: hydrogen, methyl, ethyl or benzyl; w is selected from: CH (CH)2O, S, NH, HOCH, Men or EtN; m is selected from: CH or N.
Further, a process for producing a 2-amino-4-methoxybenzoic acid derivative (I) by electroreduction, wherein the following compounds are preferred as the 2-amino-4-methoxybenzoic acid derivative:
further, a process for producing 2-amino-4-methoxybenzoic acid derivative (I) by electroreduction, wherein the following compounds are preferred for 4-methoxy-2-nitrobenzoic acid derivative (A):
further, a process for producing 2-amino-4-methoxybenzoic acid derivative (I) by electroreduction, wherein the following compounds are preferred for 4-methoxy-2-aminobenzoic acid derivative (I):
further, a process for producing 2-amino-4-methoxybenzoic acid derivative (I) by electroreduction, wherein the following compounds are preferred for 4-methoxy-2-nitrobenzoic acid derivative (A):
in order to achieve the purpose, the electro-reduction preparation method of the 2-amino-4-methoxybenzoic acid derivative (I) comprises the following steps:
in a diaphragm electrolytic cell, an acid solution of the 4-methoxy-2-nitrobenzoic acid derivative (A) is taken as a catholyte, or a mixed solution of inorganic ammonium salt, an organic solvent and water of the 4-methoxy-2-nitrobenzoic acid derivative (A) is taken as the catholyte; the acid aqueous solution is an anolyte; the cathode electrolysis product containing the 2-amino-4-methoxybenzoic acid derivative is obtained through the electro-reduction reaction.
The principle of the electro-reduction reaction of the 4-methoxy-2-nitrobenzoic acid derivative (A) is that the reaction formula of a cathode under an acidic condition is as follows:
the stepwise reaction formula is as follows:
in the step reaction formula, the structural formula (1) is taken as a raw material, and the structural formulas (2) to (5) are intermediate products or byproducts; the structural formula I is a target product, namely a 2-amino-4-methoxybenzoic acid derivative.
The reaction formula of the anode under the acidic condition is as follows:
6H2O→12H++3O2+12e-
the overall reaction formula is:
the voltage of the cathode working electrode is 1.00V-2.50V relative to the reference electrode; the current density of the cathode working electrode is 20.0mA/cm2～250.0mA/cm2To (c) to (d); the electrolysis temperature is between 20 ℃ and 80 ℃.
After the electrolysis is completed, a cathode electrolysis product containing the 2-amino-4-methoxybenzoic acid derivative shown as I is obtained.
Within the range of the working voltage and the current density of the electrode, the structural formula I is a main product, namely the 2-amino-4-methoxybenzoic acid derivative, the selectivity of the main product is highest, and the yield of the intermediate products or byproducts of the structural formulas (2) to (5) is lowest.
Preferably, the reference electrode of the diaphragm electrolyzer is: a saturated potassium chloride calomel electrode.
The cathode of the diaphragm electrolytic cell is as follows: brass electrodes, red copper electrodes, titanium mesh electrodes, nickel, lead, platinum or graphite electrodes.
The anode of the diaphragm electrolytic cell is: a DSA electrode or a titanium-based platinum electrode; the DSA electrode and the metal oxide anode are mainly oxides of titanium, manganese, cobalt, noble metals such as ruthenium and iridium, and the matrix is titanium.
The diaphragm of the diaphragm electrolytic cell is as follows: HF-101 strong acid cation exchange membrane.
The organic solvent in the catholyte is any one or more of ethyl acetate, C1-C5 straight-chain alcohol, C2-C5 branched-chain alcohol and acetonitrile.
Preferably, the concentration of the 4-methoxy-2-nitrobenzoic acid derivative (A) in the catholyte is between 2.0g/L and 16.0 g/L. In the cathode electrolyte, the concentration of the 4-methoxy-2-nitrobenzoic acid derivative (A) is too high, the dissolution is not good, and the reduction reaction is not favorably carried out; if the concentration is too low, the equipment utilization rate and the reduction reaction efficiency are lowered. The concentration of the acid within the range can ensure the dissolution of the 4-methoxy-2-nitrobenzoic acid derivative (A), provide good conductivity of the electrolyte and sufficient proton and electron generation, and facilitate the post-treatment of the electric reduction product.
The acidic aqueous solution serves as an electrolyte for the electro-reduction reaction, and the catholyte has suitable conductivity in this concentration range.
Preferably, the catholyte is a phosphoric acid solution, a sulfuric acid solution or a hydrochloric acid solution containing the 4-methoxy-2-nitrobenzoic acid derivative (A), and the acid solution is favorable for supplying and transferring protons.
Preferably, the catholyte is a mixed solution of inorganic ammonium salt containing the 4-methoxy-2-nitrobenzoic acid derivative (A), an organic solvent and water; the inorganic ammonium salt in the catholyte is: ammonium chloride, ammonium sulfate, ammonium nitrate, ammonium carbonate, ammonium bromide, or ammonium iodide; ammonium ions have good conductivity.
Preferably, the anolyte is a phosphoric acid solution, a sulfuric acid solution or a hydrochloric acid solution, and the acidic solution is favorable for supplying and transferring protons.
Preferably, the liquid levels of the catholyte and the anolyte are at the same level.
The beneficial technical effects are as follows:
the invention relates to an electroreduction preparation method of an anticancer drug gefitinib and an analogue intermediate 2-amino-4-methoxybenzoic acid derivative (I), and the electroreduction preparation method of the 2-amino-4-methoxybenzoic acid derivative has the following advantages:
(1) no toxic or dangerous reducing agent is needed in the reduction reaction, and the 'electron' is a clean reaction reagent and is an important component for developing the 'green pharmaceutical industry'.
(2) During the electroreduction process, the conversion rate and selectivity can be controlled by changing the electrode potential; thereby obtaining the intermediate with high purity and high yield.
(3) In industrial production, the process flow is simplified, the production cost is reduced, and the method is safe and environment-friendly and is suitable for large-scale popularization and application.
(4) The electro-reduction of the 4-methoxy-2-nitrobenzoic acid derivative (A) in part does not require the use of organic solvents.
Toxic or dangerous reducing agents are not needed in the electro-reduction reaction, and the method is an important component for developing the green pharmaceutical industry; by varying the electrode potential, the conversion and selectivity can be controlled, thereby obtaining high purity and high yield intermediates.
Drawings
FIG. 1 is a schematic view of a diaphragm electrolyzer
Detailed Description
The following examples are intended to illustrate the invention without further limiting it.
Example 1
Preparation of 2-amino-4-methoxy-5- (3-chloropropoxy) methyl benzoate by electroreduction
A separate electrolytic cell was installed (fig. 1). A magnetic stirrer is added into a cathode (Cu) electrolytic tank, 0.45g of 4-methoxy-5- (3-chloropropoxy) -2-nitrobenzoic acid methyl ester is completely dissolved in 60mL of methanol, 60mL of a 0.5mol/L hydrochloric acid solution or a solution prepared from 6.0g of ammonium chloride and 60mL of water is added, and 120mL of a 0.25mol/L sulfuric acid solution is added into an anode (DSA) electrolytic tank. The effective electrode areas of the cathode (Cu) and the anode (DSA) were each 4cm2Controlling the current at two ends of the anode and the cathode to be 0.3A, and carrying out constant current electrolysis with the constant current density of 75mA/cm2The voltage between the cathode and the reference is 1.1-1.4V; stirring the mixture in a water bath at 40 ℃ for an electro-reduction reaction for 4 hours, taking out a cathode solution, adjusting the cathode solution to be alkalescent by using a 10% NaOH solution, extracting the mixture for 2 times by using dichloromethane, drying the mixture by using anhydrous sodium sulfate, carrying out suction filtration, carrying out solvent desolventization, and drying the mixture to obtain 0.38g of 2-amino-4-methoxy-5- (3-chloropropoxy) methyl benzoate, wherein the melting point is 97-99 ℃, and the yield is 93.8%;1H NMR(400MHz，CDCl3)δ：7.36(s，1H，C6H2 6-H)，6.15(s，1H，C6H2 3-H)，4.08(t，J＝6.0Hz，2H，OCH2)，3.85(s，3H，COOCH3)，3.84(s，3H，OCH3)，3.77(t，J＝6.4Hz，2H，ClCH2)，2.21～2.27(m，2H，CH2)。1H NMR(400MHz，DMSO-D6)δ：7.17(s，1H，C6H26-H)，6.50(s，1H，NH2)，6.37(s，1H，C6H2 3-H)，3.92(t，J＝6.0Hz，2H，OCH2)，3.78(t，J＝6.4Hz，2H，ClCH2)，3.75(s，3H，COOCH3)，3.74(s，3H，OCH3)，2.07～2.13(m，2H，CH2)。
example 2 (control experiment)
Preparation of methyl 2-amino-4-methoxy-5- (3-chloropropoxy) benzoate
Reduction of methyl 4-methoxy-5- (3-chloropropoxy) -2-nitrobenzoate using iron powder and acetic acid to give methyl 2-amino-4-methoxy-5- (3-chloropropoxy) benzoate, melting point: 96-98 ℃ and the yield is 77%.
Example 3
Preparation of 2-amino-4-methoxy-5- (3-morpholinylpropoxy) methyl benzoate by electroreduction
In the diaphragm type electrolytic cell shown in FIG. 1, a magnetic stirrer, 0.50g of 4-methoxy-5- (3-morpholinopropoxy) -2-nitrobenzoic acid methyl ester and 120mL of a 0.5mol/L hydrochloric acid solution were added to a cathode (Cu) electrolytic cell, and stirred to be completely dissolved, and 120mL of a 0.25mol/L sulfuric acid solution was added to an anode (DSA) electrolytic cell. The cathode uses Saturated Calomel Electrode (SCE) as reference electrode, constant voltage between cathode and reference is controlled to be 2.0V, and effective electrode areas of cathode (Cu) and anode (DSA) are respectively 4cm2The current density is 60mA/cm2(ii) a Stirring the mixture in a water bath at 40 ℃ for an electro-reduction reaction for 3.0h, taking out a cathode solution, adjusting the mixture to be alkalescent by using a 10% NaOH solution, extracting the mixture for 2 times by using dichloromethane, drying the mixture by using anhydrous sodium sulfate, carrying out suction filtration, carrying out solvent desolventization, and drying the mixture to obtain 0.45g of 2-amino-4-methoxy-5- (3-morpholinylpropoxy) methyl benzoate, wherein the melting point is 90-92 ℃, and the yield is 98.3%;1H NMR(400MHz，CDCl3)δ：1.97～2.02(m，2H，CH2)，2.48(t，J＝4.6Hz，4H，CH2NCH2)，2.54(t，J＝7.2Hz，2H，NCH2)，3.73(t，J＝4.6Hz，4H，CH2OCH2)，3.84(s，3H，OCH3)，3.85(s，3H，COOCH3)，4.01(t，J＝6.4Hz，2H，OCH2)，5.60(s，2H，NH2)，6.14(s，1H，C6H2 3-H)，7.34(s，1H，C6H2 6-H)。
example 4 (control experiment)
Preparation of methyl 2-amino-4-methoxy-5- (3-morpholinylpropoxy) benzoate
The compound is prepared by a method of a document [ Novel preparation of gefitinib. J Chem Res,2009: 388-390 ], and sodium hydrosulfite (sodium hydrosulfite) is adopted to reduce 4-methoxy-5- (3-morpholinylpropoxy) -2-nitrobenzoic acid methyl ester to obtain 2-amino-4-methoxy-5- (3-morpholinylpropoxy) benzoic acid methyl ester, the melting point is 89-90 ℃, and the yield is 90%.
Example 5
Preparation of ethyl 2-amino-4-methoxy-5- (3-morpholinylpropoxy) benzoate by electroreduction
Ethyl 4-methoxy-5- (3-morpholinopropoxy) -2-nitrobenzoate was electroreduced as in example 3 to give ethyl 2-amino-4-methoxy-5- (3-morpholinopropoxy) carboxylate.
Example 6 (use or application)
Preparation of gefitinib
Referring to [ a preparation method of gefitinib, CN 102030716a, 2011-04-27], gefitinib is prepared according to the following route:
example 7
Preparation of 2-amino-4-methoxy-5- (3-morpholinylpropoxy) benzamide by electroreduction
4-methoxy-5- (3-morpholinopropoxy) -2-nitrobenzamide was electroreduced as in example 3 to give 2-amino-4-methoxy-5- (3-morpholinopropoxy) benzamide.
Wherein the 4-methoxy-5- (3-morpholinylpropoxy) -2-nitrobenzamide is prepared according to a method of a document [ the research of the gefitinib synthesis process, China journal of pharmacy 2012, 47(13):1084-1087 ].
Example 8
Preparation of 2-amino-4-methoxy-5- (3-morpholinylpropoxy) benzonitrile by electroreduction
4-methoxy-5- (3-morpholinopropoxy) -2-nitrobenzonitrile was electroreduced as in example 3 to give 2-amino-4-methoxy-5- (3-morpholinopropoxy) benzonitrile.
Wherein, the 4-methoxy-5- (3-morpholinylpropoxy) -2-nitrobenzonitrile is prepared according to the method of the literature [ the synthesis process research of gefitinib and erlotinib, Shenyang pharmaceutical university Master thesis, 2008 ].
The electro-reduction preparation method of the 2-amino-4-methoxybenzoic acid derivative simplifies the process flow and reduces the production cost in industrial production, basically has no pollution to the environment, and is suitable for large-scale popularization and application.
In the present specification, the invention has been described with reference to specific embodiments thereof. It will, however, be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention. The specification and drawings are, accordingly, to be regarded in an illustrative rather than a restrictive sense.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911078871.4A CN110747489B (en) | 2019-11-07 | 2019-11-07 | Preparation method of anticancer drug gefitinib and intermediates of its analogs by electroreduction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911078871.4A CN110747489B (en) | 2019-11-07 | 2019-11-07 | Preparation method of anticancer drug gefitinib and intermediates of its analogs by electroreduction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110747489A CN110747489A (en) | 2020-02-04 |
| CN110747489B true CN110747489B (en) | 2021-05-07 |
Family
ID=69282443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911078871.4A Active CN110747489B (en) | 2019-11-07 | 2019-11-07 | Preparation method of anticancer drug gefitinib and intermediates of its analogs by electroreduction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110747489B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110438521B (en) * | 2019-07-15 | 2021-09-21 | 华南理工大学 | Method for selectively demethylating N-methyl-N- (2-cyanoethyl) aniline under electrochemical condition |
| CN112079812B (en) * | 2020-09-29 | 2021-08-06 | 浙江大学 | Key intermediates of piperazole antipsychotics and methods for their electroreduction |
| CN112125896B (en) * | 2020-09-29 | 2021-10-29 | 湖南省湘中制药有限公司 | Electrochemical preparation method of antipsychotic drug brexpiprazole |
| CN112251770B (en) * | 2020-10-14 | 2021-07-27 | 湖南大学 | A new method for electrochemical preparation of an intermediate of antihypertensive drug telmisartan |
| CN113308704B (en) * | 2021-05-31 | 2022-04-08 | 湖南大学 | Electrooxidative preparation method of naproxen intermediate |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1115755A (en) * | 1993-10-02 | 1996-01-31 | 默克专利股份有限公司 | Method for preparing 3-aminopyridines from 3-nitropyridines |
| CN101148439A (en) * | 2007-09-14 | 2008-03-26 | 东南大学 | A kind of preparation method of gefitinib |
| CN101187031A (en) * | 2007-09-18 | 2008-05-28 | 华东师范大学 | Electrochemical Synthesis of 1,5-Diaminonaphthalene |
| CN101187032A (en) * | 2007-09-20 | 2008-05-28 | 华东师范大学 | The electrochemical synthesis method of p-aminoanisole |
| CN101457368A (en) * | 2008-12-20 | 2009-06-17 | 乐威（泰州）医药化学品有限公司 | Technical method for synthesizing 4-fluoroaniline by electrochemistry method |
| CN100529190C (en) * | 2006-11-03 | 2009-08-19 | 华东理工大学 | O-nitrophenol electrolyzing reduction process for preparing O-aminophenol |
| CN102030716A (en) * | 2009-09-30 | 2011-04-27 | 中山大学 | Method for preparing gefitinib |
| WO2011147102A1 (en) * | 2010-05-28 | 2011-12-01 | 翔真生物科技股份有限公司 | Synthetic method for 6,7-substituents-4-aniline quinazoline |
| CN102146060B (en) * | 2010-02-09 | 2013-07-03 | 陕西师范大学 | Method for preparing gefitinib and intermediate thereof |
| CN103304491A (en) * | 2013-06-17 | 2013-09-18 | 连云港盛和生物科技有限公司 | Preparation method of gefitinib |
| CN103570633A (en) * | 2012-07-27 | 2014-02-12 | 中国科学院广州生物医药与健康研究院 | Preparation method of gefitinib |
| CN105218463A (en) * | 2014-05-30 | 2016-01-06 | 沈阳药科大学 | The synthetic method of Gefitinib |
| CN108503597A (en) * | 2018-05-16 | 2018-09-07 | 济南爱思医药科技有限公司 | A kind of high efficiency preparation method of Gefitinib |
-
2019
- 2019-11-07 CN CN201911078871.4A patent/CN110747489B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1115755A (en) * | 1993-10-02 | 1996-01-31 | 默克专利股份有限公司 | Method for preparing 3-aminopyridines from 3-nitropyridines |
| CN100529190C (en) * | 2006-11-03 | 2009-08-19 | 华东理工大学 | O-nitrophenol electrolyzing reduction process for preparing O-aminophenol |
| CN101148439A (en) * | 2007-09-14 | 2008-03-26 | 东南大学 | A kind of preparation method of gefitinib |
| CN101187031A (en) * | 2007-09-18 | 2008-05-28 | 华东师范大学 | Electrochemical Synthesis of 1,5-Diaminonaphthalene |
| CN101187032A (en) * | 2007-09-20 | 2008-05-28 | 华东师范大学 | The electrochemical synthesis method of p-aminoanisole |
| CN101457368A (en) * | 2008-12-20 | 2009-06-17 | 乐威（泰州）医药化学品有限公司 | Technical method for synthesizing 4-fluoroaniline by electrochemistry method |
| CN102030716A (en) * | 2009-09-30 | 2011-04-27 | 中山大学 | Method for preparing gefitinib |
| CN102146060B (en) * | 2010-02-09 | 2013-07-03 | 陕西师范大学 | Method for preparing gefitinib and intermediate thereof |
| WO2011147102A1 (en) * | 2010-05-28 | 2011-12-01 | 翔真生物科技股份有限公司 | Synthetic method for 6,7-substituents-4-aniline quinazoline |
| CN103570633A (en) * | 2012-07-27 | 2014-02-12 | 中国科学院广州生物医药与健康研究院 | Preparation method of gefitinib |
| CN103304491A (en) * | 2013-06-17 | 2013-09-18 | 连云港盛和生物科技有限公司 | Preparation method of gefitinib |
| CN105218463A (en) * | 2014-05-30 | 2016-01-06 | 沈阳药科大学 | The synthetic method of Gefitinib |
| CN108503597A (en) * | 2018-05-16 | 2018-09-07 | 济南爱思医药科技有限公司 | A kind of high efficiency preparation method of Gefitinib |
Non-Patent Citations (2)
| Title |
|---|
| 吉非替尼的合成研究;徐国权等;《化学与生物工程》;20110125;第28卷(第1期);第20-22页 * |
| 抗肿瘤药物吉非替尼的合成方法研究;孙键等;《化学研究与应用》;20130815;第25卷(第8期);第1180-1184页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110747489A (en) | 2020-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110747489B (en) | Preparation method of anticancer drug gefitinib and intermediates of its analogs by electroreduction | |
| CN110629246B (en) | Vantanib and analogue intermediate electro-reduction preparation method thereof | |
| Ruan et al. | Late-stage azolation of benzylic C‒H bonds enabled by electrooxidation | |
| CN104087968B (en) | selective electrochemical reduction method of halogenated picolinic acid or salt compound thereof | |
| JP5535215B2 (en) | Method for anodic dehydrogenation dimerization of substituted aryl alcohols | |
| CN111041516B (en) | A new method for the preparation of intermediates of antihypertensive drug telmisartan | |
| CN110777391B (en) | Electric reduction preparation method of gefitinib intermediate | |
| CN105887128B (en) | A kind of method of penta chloropyridine electro-catalysis selective hydration dechlorination | |
| Zhang et al. | Electrochemically Induced Regio‐and Stereoselective (E)‐β‐C (sp2)− H Trifluoromethylation and Arylsulfonylation of Enamides | |
| CN105483749B (en) | The paired electrosynthesis method of thiocyanogen α, β the unsaturated carbonyl class compound of 3 amido 2 | |
| JPH09286774A (en) | 2-alkylmercapto-4-(trifluoromethyl) benzoic acid ester and its production | |
| CN111005033B (en) | Electro-reduction preparation method of sildenafil intermediate | |
| CN111705329B (en) | A kind of electrochemical synthesis method of 5-arylthiouracil compound | |
| CN110616439B (en) | Method for synthesizing 4-sulfonic acid substituted isoquinolone derivative through electrochemical oxidation | |
| CN101603179B (en) | Electrolytic synthesis method of 3,5,6-trichloropyridine carboxylic acid | |
| CN112301371B (en) | Method for synthesizing anisyl nitrile by indirect electrocatalysis | |
| CN101187032A (en) | The electrochemical synthesis method of p-aminoanisole | |
| EP2751308B1 (en) | Process for cathodic deoxygenation of amides and esters | |
| CN105217740B (en) | A kind of Electrochemical hydriding processing method of the waste water of fluorinated aromatic hydrocarbon containing low concentration | |
| CN101591787A (en) | A kind of electrochemical synthesis method of aminophenylarsine | |
| JPH07188962A (en) | Production of 3-aminopyridines from 3- nitropyridines | |
| CN106187787A (en) | A kind of preparation method of 2 amino 4 chlorodiphenyl ethers | |
| CN110656347B (en) | Electroreduction preparation method of olanzapine intermediate | |
| JPS6342713B2 (en) | ||
| CN112853384B (en) | Method for synthesizing ibuprofen intermediate by taking halogen ions as electrocatalyst |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |